Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript
02:39pm, Wednesday, 14'th Aug 2024
Invivyd, Inc. (NASDAQ:IVVD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Katie Falzone - VP, Corporate Controller Marc Elia - Chairperson, Board of Directors and E
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
10:11am, Wednesday, 14'th Aug 2024
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.46 per share a year ago.
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08:01am, Wednesday, 14'th Aug 2024
WALTHAM, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced fin
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
04:01pm, Monday, 12'th Aug 2024
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced tha
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
07:01am, Monday, 01'st Jul 2024
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced tha
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
07:01am, Friday, 14'th Jun 2024
WALTHAM, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced tha
Invivyd to Participate at the Jefferies Global Healthcare Conference
04:01pm, Monday, 03'rd Jun 2024
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced tha
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
07:05am, Friday, 31'st May 2024
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced gene
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
07:00am, Friday, 31'st May 2024
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced th
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
07:00am, Wednesday, 29'th May 2024
WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that
Invivyd Elects Two New Independent Members to its Board of Directors
07:00am, Wednesday, 22'nd May 2024
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
04:01pm, Monday, 13'th May 2024
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that
Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript
08:37pm, Saturday, 11'th May 2024
Invivyd, Inc. (NASDAQ:IVVD ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Scott Young - Vice President of Investor Relations & Corporate Communications Marc Elia - Chair
IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024
10:56pm, Thursday, 09'th May 2024
Invivyd (NASDAQ: IVVD ) just reported results for the first quarter of 2024. Invivyd reported earnings per share of -38 cents.
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
04:01pm, Thursday, 09'th May 2024
WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced fina
